Mikala Egeblad, PhD; Melissa A. Simon, MD, MPH; and Ryan B. Corcoran, MD, PhD, reviewed six days of sessions on basic cancer science and translational research; prevention, early detection, population sciences, and disparities research; and clinical research and clinical trials.

Three special sessions organized by the AACR Chemistry in Cancer Research (CICR) Working Group offered a first look at the structure, mechanism of action, and functional target modulation of novel cancer agents.

Jean Abraham, PhD, and other researchers presented findings on the efficacy and safety of PARP inhibitors and other targeted cancer treatments during a clinical trials plenary session.

Mohummad Aminur Rahman, PhD, and other presenters discussed study data on biomarkers to identify potential patient subgroups for novel combination therapies.

James P. Allison, PhD, FAACR, and a panel of distinguished scientists shared insights into immune checkpoint blockades, cancer vaccines, CRISPR-modified CAR T cells, and CD4 T cells.

Tatsuhiro Shibata, MD, PhD, presented recent data on the driver gene landscape in a large dataset of gastric cancer patients, including those of East Asian and Eastern European ancestry, during a special joint session with the Japanese Cancer Association (JCA).

Angela M. DeMichele, MD, examined strategies to therapeutically target dormant and reactivated MRD to prevent cancer recurrence during a special joint session with the American Society of Clinical Oncology (ASCO).

Elizabeth Travis, PhD, was honored with the AACR-Women in Cancer Research Charlotte Friend Lectureship award in recognition of her trailblazing research on the effects of radiation on normal tissues, as well as for her devotion to championing women in science and medicine.

Chi Van Dang, MD, PhD, FAACR, received the AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research in recognition of his notable contributions towards defining the function of the MYC oncogene.